Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Ladies and gentlemen, thank you for standing by and welcome. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question-and-answer session. Please be advised that today's conference call may be recorded. I would now like to hand the conference call over to Anne-Marie Fields, Managing Director at Precision AQ. Please go ahead. Thank you, Vanessa. Good morning, and welcome to Selectar Biosciences' first quarter 2026 Financial Results and Business Update conference call. Joining us today from Selectar are Jim Caruso, President and CEO, who will provide an overview of the company's progress before turning the call over to Chad Colleen, CFO, for a financial review of the quarter. Following this, Jared Lancourt, Chief Operating Officer, will give an update on the company's progress and plans for its promising clinical development pipeline at Radio Pharmaceutical. SelectArt issued a press release earlier this morning detailing the company's call. A copy can be found on the industry page of SelectArt's corporate website. I want to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press and in the SEC filing. The content of this conference call contains time-sensitive information tha...